Research programme: glaucoma therapeutics - Colby Pharmaceuticals

Drug Profile

Research programme: glaucoma therapeutics - Colby Pharmaceuticals

Alternative Names: OT-411; OT-440

Latest Information Update: 13 Dec 2012

Price : $50

At a glance

  • Originator Othera Pharmaceuticals
  • Developer Colby Pharmaceuticals
  • Class Hydroxylamines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Glaucoma

Most Recent Events

  • 13 Dec 2012 The development of OT 440 will be continued by Colby Pharmaceuticals
  • 19 Sep 2012 Colby Pharmaceuticals acquires Othera Pharmaceuticals
  • 04 May 2010 Preclinical trials in Glaucoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top